These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17229642)

  • 1. Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients.
    Pelizzari AM; Drera M; D'Adda M; Ungari M; Marocolo D; Facchetti F; Bellotti D; Barlati S; Rossi G
    Haematologica; 2007 Jan; 92(1):106-9. PubMed ID: 17229642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.
    Heil G; Hoelzer D; Sanz MA; Lechner K; Liu Yin JA; Papa G; Noens L; Szer J; Ganser A; O'Brien C; Matcham J; Barge A
    Blood; 1997 Dec; 90(12):4710-8. PubMed ID: 9389686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
    Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich EJ; Andersson BS; O'Brien S; Andreeff M; Fisher H; Cork A
    N Engl J Med; 1993 Sep; 329(11):757-61. PubMed ID: 7688862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
    Chen C; Xu W; Yang J
    Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
    Bradley AM; Deal AM; Buie LW; van Deventer H
    Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilineage response in aplastic anemia patients following long-term administration of filgrastim (recombinant human granulocyte colony stimulating factor).
    Sonoda Y; Ohno Y; Fujii H; Takahashi T; Nakayama S; Haruyama H; Nasu K; Shimazaki C; Hara H; Kanamaru A
    Stem Cells; 1993 Nov; 11(6):543-54. PubMed ID: 7509223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
    Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
    N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colony-stimulating factors: beyond the effects on hematopoiesis.
    Stull DM
    Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S12-20. PubMed ID: 11944610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
    Feng X; Lan H; Ruan Y; Li C
    Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia.
    Jakubowski A; Gordon M; Tafuri A; Schuster S; Andreeff M; Shieh JH; Vincent M; Gabrilove J
    Leukemia; 1995 Nov; 9(11):1799-804. PubMed ID: 7475265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.
    Weiss M; Voglic S; Harms-Schirra B; Lorenz I; Lasch B; Dumon K; Gross-Weege W; Schneider EM
    Intensive Care Med; 2003 Jun; 29(6):904-914. PubMed ID: 12682721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
    Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
    Derbel O; Cannas G; Le QH; Elhamri M; Chelghoum Y; Nicolas-Virelizier E; Nicolini F; Troncy J; Barraco F; Michallet M; Thomas X
    Hematology; 2010 Jun; 15(3):125-31. PubMed ID: 20557669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia.
    Wang J; de Lima M; Cooper BW; Boughan K; Metheny L; Otegbeye F; Caimi PF; Gallogly M; Malek E; Cao S; Fu P; Glotzbecker B; Schiltz NK; Tomlinson BK
    Leuk Lymphoma; 2021 Jun; 62(6):1450-1457. PubMed ID: 33461376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.